Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 974

Sort by

Sort Order Select

Journal Articles

Erdheim-Chester disease

Julien Haroche, Fleur Cohen-Aubart, Zahir Amoura

Blood (2020) 135 (16): 1311–1318.

https://doi.org/10.1182/blood.2019002766

Published: 2020

Journal Articles

Efficacy and Safety of Direct Oral Factor Xa Inhibitors in Patients after Bariatric Surgery

Margarita Kushnir, MD, Radhika Gali, MD, Mariam Alexander, MD, Henny Heisler H. Billett, MD

Blood (2019) 134 (Supplement_1): 2439.

https://doi.org/10.1182/blood-2019-127645

Published: 2019

Journal Articles

Natural History of Tumor Thrombus: A Single-Centre Retrospective Study

Curtis Marcoux, MD MSc, Shahad Al Ghamdi, MD, Daria Manos, MD, Mary-Margaret Keating, MD, Sudeep P Shivakumar, MD BSc

Blood (2019) 134 (Supplement_1): 2430.

https://doi.org/10.1182/blood-2019-124476

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Gastrointestinal (GI) Involvement with Non-Hodgkin's Lymphoma (NHL) Impacts Outcome; A Retrospective Single Tertiary Care Center Analysis of Clinico-Pathologic Characteristics Provides an Alternate Insight to Presentation and Outcome

Ghada Zakout, FRCPATH, MRCP (UK), MBBCh (Hon), Charalampia Kyriakou

Blood (2019) 134 (Supplement_1): 5246.

https://doi.org/10.1182/blood-2019-127152

Published: 2019

Journal Articles

Brentuximab Vedotin As Consolidation Therapy Post Hematopoietic Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma: A Real World Analysis of the Colombian Experience

Blood (2019) 134 (Supplement_1): 5275.

https://doi.org/10.1182/blood-2019-129295

Published: 2019

Journal Articles

Comparison of CT and PET-Based Assessments per Lugano Criteria in FDG-Avid Lymphoma- a Retrospective Analysis of Independent Review Assessments

Jayant Narang, MD, Surabhi Bajpai, MD, Rudresh Rajnikant Jarecha, MBBS, MD, Sayali Karve, PhD, Katarina Ludajic, PhD, Manish Sharma, MD, Shweta Narang, MD, Michael O'Connor, PhD

Blood (2019) 134 (Supplement_1): 5277.

https://doi.org/10.1182/blood-2019-130570

Published: 2019

Journal Articles

Real Life Use of Imaging in the Management of Newly Diagnosed Patients with Myeloma- Practical Perspectives from a UK Hospital

Ke Xu, MD, Lucy Fowkes, Fenella Willis, Yasmin Reyal

Blood (2019) 134 (Supplement_1): 5513.

https://doi.org/10.1182/blood-2019-121504

Published: 2019

Journal Articles

Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality

Ko Ko Ko Maung, MD, Mohammad Chaudhry, MD, Yi Ren, MS, Sin-Ho Jung, PhD, Kristi M. Romero, BS, Kelly Corbet, BS, Nelson J. Chao, MD, Taewoong Choi, MD, Anna Mae Diehl, MD, Louis F. Diehl, MD, Cristina Gasparetto, MD, Mitchell E. Horwitz, MD, Gwynn D. Long, MD, Richard D. Lopez, MD, David A. Rizzieri, MD, Stefanie Sarantopoulos, MD PhD, Keith Sullivan, MD, Mustafa R. Bashir, MD, Anthony D. Sung, MD

Blood (2019) 134 (Supplement_1): 5731.

https://doi.org/10.1182/blood-2019-121830

Published: 2019

Journal Articles

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

Blood (2019) 134 (Supplement_1): 2618.

https://doi.org/10.1182/blood-2019-130642

Published: 2019

Journal Articles

Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R

Vania Phuoc, MD, Leidy Isenalumhe, MD, Hayder Saeed, MD, Celeste Bello, MD, Bijal Shah, MD, Lubomir Sokol, MD PhD, Julio Chavez

Blood (2019) 134 (Supplement_1): 2898.

https://doi.org/10.1182/blood-2019-122393

Published: 2019

Journal Articles

Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)

Blood (2019) 134 (Supplement_1): 3046.

https://doi.org/10.1182/blood-2019-125895

Published: 2019

Journal Articles

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Juan Carlos Ramos, MD BS, Richard F. Ambinder, MD, Joseph Sparano, MD, Jeannette Y Lee, PhD, Lawrence D Kaplan, MD, William Wachsman, MD PhD, David M. Aboulafia, MD, Ariela Noy, MD, Lee Ratner, MD PhD, David H. Henry, MD, Amy Chadburn, MD, Ethel Cesarman, MD PhD, Ronald T. Mitsuyasu, MD

Blood (2019) 134 (Supplement_1): 2872.

https://doi.org/10.1182/blood-2019-123558

Published: 2019

Journal Articles

The Effect of Diagnostic Wait Time on the Survival of Patients with Diffuse Large B-Cell Lymphoma Differs Depending on International Prognostic Index

Shin Lee, MD, Negoro Eiju, Morishita Tetsuji, MD PhD, Kei Fujita, MD, Hideaki Yamauchi, MD, Kana Oiwa, MD, Takanori Ueda, MD PhD, Takahiro Yamauchi, MD PhD

Blood (2019) 134 (Supplement_1): 2902.

https://doi.org/10.1182/blood-2019-121527

Published: 2019

Journal Articles

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Kerry A Rogers, MD, Lai Wei, PhD, Seema A. Bhat, MD, Dan Jones, MD PhD, Erlene K. Seymour, MD, Deborah M. Stephens, DO, J Christine Ye, MDMSc, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 3049.

https://doi.org/10.1182/blood-2019-125360

Published: 2019

Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H. Park, MD, Madhulika Shukla, Jose M Salcedo, Shreya Vemuri, Julie C Kinoshita, Marissa D Smith, Eric S. Winer, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 3998.

https://doi.org/10.1182/blood-2019-124478

Published: 2019

Journal Articles

Utility of Bone Marrow Biopsy in the Staging of T-Cell Lymphoma in the PET-CT Era

Suchitra Sundaram, MD, Matthew Gravina, MD, Kristopher Attwood, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Pallawi Torka, MD

Blood (2019) 134 (Supplement_1): 4039.

https://doi.org/10.1182/blood-2019-130382

Published: 2019

Journal Articles

Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)

Mariana Bastos-Oreiro, MD PhD, Nieves Lopez, Pilar Gomez, Liébana Marta, Laura LLorente, MD, Antonio Gutiérrez, EVA Domingo Domenech, PhD, Maria Jesus Vidal Maceñido, MD, Raquel Del Campo, Leyre Bento, Daniel Garcia, Miriam Santero, Jaime Perez De Oteyza, MD PhD, Belén Navarro, MD, Antonia Rodriguez Izquierdo, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 4040.

https://doi.org/10.1182/blood-2019-125813

Published: 2019

Journal Articles

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Sanjal Desai, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Mark A. Ahlman, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 4102.

https://doi.org/10.1182/blood-2019-127481

Published: 2019

Journal Articles

Real Life CNS-IPI Score Validation: A Retrospective Analysis of Two Centers in Brazil Outside of Clinical Trial

Thais Fischer, MD, Natalia Pin Chuen Zing, MD, Sérgio Costa Fortier, MD, Talita Silveira, Carlos Sérgio Chiattone, MD

Blood (2019) 134 (Supplement_1): 4133.

https://doi.org/10.1182/blood-2019-125576

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Erdheim-Chester disease

Efficacy and Safety of Direct Oral Factor Xa Inhibitors in Patients after Bariatric Surgery

Natural History of Tumor Thrombus: A Single-Centre Retrospective Study

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Gastrointestinal (GI) Involvement with Non-Hodgkin's Lymphoma (NHL) Impacts Outcome; A Retrospective Single Tertiary Care Center Analysis of Clinico-Pathologic Characteristics Provides an Alternate Insight to Presentation and Outcome

Brentuximab Vedotin As Consolidation Therapy Post Hematopoietic Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma: A Real World Analysis of the Colombian Experience

Comparison of CT and PET-Based Assessments per Lugano Criteria in FDG-Avid Lymphoma- a Retrospective Analysis of Independent Review Assessments

Real Life Use of Imaging in the Management of Newly Diagnosed Patients with Myeloma- Practical Perspectives from a UK Hospital

Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R

Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

The Effect of Diagnostic Wait Time on the Survival of Patients with Diffuse Large B-Cell Lymphoma Differs Depending on International Prognostic Index

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Utility of Bone Marrow Biopsy in the Staging of T-Cell Lymphoma in the PET-CT Era

Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Real Life CNS-IPI Score Validation: A Retrospective Analysis of Two Centers in Brazil Outside of Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only